Studying Blood Cell Growth Patterns and Heart Health After Hodgkin Lymphoma Treatment
Studies blood cell growth changes and heart health in people treated for Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who were treated for classic Hodgkin lymphoma as children or young adults. They must have had a high dose of anthracycline chemotherapy and finished all cancer treatment at least 2 years ago.
- Age
- 7 years or older at enrollment. Hodgkin lymphoma must have been diagnosed at age 2 or older and under 22.
- Sex
- All sexes can join.
- Disease stage
- Past pathologically confirmed classical Hodgkin lymphoma, with no relapse, second cancer or death known.
- Earlier treatment
- Must have received a cumulative doxorubicin equivalent anthracycline dose of 200 mg/m^2 or more as first treatment. All systemic cancer treatment must have ended at least 2 years before joining.
Main reasons for not taking part
- Medical reason that makes a non-contrast cardiac MRI unsafe
- Nodular lymphocyte-predominant Hodgkin lymphoma
- Cancer treatment beyond that for the first Hodgkin lymphoma
- Serious heart condition (grade 3 or higher) before the Hodgkin lymphoma diagnosis
- Immune deficiency before the Hodgkin lymphoma diagnosis, including organ transplant or immune-suppressing medicine
Read by machine on 12 November 2026.
Where in Canada
- Hospital for Sick ChildrenToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Children's Oncology Group
- Trial code
- NCT05705531
- Record updated
- 25 August 2026
- Original description
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.Read full original descriptionShow less
Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors
This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.
Inclusion: Patient must be >= 7 years of age at the time of enrollment (age to perform an MRI without sedation); History of pathologically confirmed classical Hodgkin Lymphoma (cHL) initially diagnosed when the patient was >= 2 and < 22 years of age; As part of frontline therapy for cHL, the patient must have received a cumulative doxorubicin equivalent anthracycline dose of ≥ 200 mg/m\^2 as estimated in doxorubicin isotoxic equivalents dose conversion calculation; Note: History of COG therapeutic trial participation is not required. Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used as reference documentation of receipt of anthracycline dose; All systemic cancer treatment must have been completed ≥ 2 years prior to study enrollment; Not known to have had a primary event (relapse/second malignancy/death); Note: Subjects treated at another institution are eligible if they are now being followed at the current COG institution, if the study procedures can be performed and the data accessible by a COG institution where the study is open; Patient must have access to cardiac MRI at the enrolling institution and must be able to complete cardiac MRI without sedation.
Exclusion: Received cancer therapy in addition to that for primary Hodgkin Disease (e.g., for disease progression or recurrence, or subsequent malignant neoplasm); History of CTCAE grade 3 or higher cardiovascular disease or condition known to exist prior to the patient's initial diagnosis of cHL; Note: exceptions are made for congenital conditions considered fully resolved by surgery and chronic conditions such as hypertension or hypercholesterolemia that are managed with medical intervention; History of an immunodeficiency that existed prior to cHL diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and conditions requiring systemic immunosuppressive agents; Medical contraindication to undergoing a non-contrast cardiac MRI; Patients with nodular lymphocyte-predominant HL.